A7: There are exciting therapies currently in clinical trials that prevent the liver from making apo(a) and thereby reducing lipoprotein(a) levels by ~80% at optimal doses. Pelacarsen is currently in phase III and Oliparsiran in phase II clinical trials. #Knowlpa

#knowlpa American Heart Association ATVB: An AHA Journal Marlys Koschinsky Don Lloyd-Jones Calvin Yeang MD, PhD

Kicking things off at National Lipid Association CLU 2023 with a fantastic session on Lp(a) Marlys Koschinsky Christie Ballantyne Michael D. Shapiro Calvin Yeang MD, PhD

UC San Diego Cardiology Harpreet Bhatia Sam Tsimikas, MD Dr. James Underberg Pam R. Taub, MD❤️💃🏻 Erin D. Michos, M.D. Nathan Wong Pradeep Natarajan Eugenia Gianos MD Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA Dan Soffer

🚨In our study of >5.5 million patients across California, only 0.3% had Lp(a) tested from 2012-2021. Only 3% with family history and <4% with personal history of CVD were tested. JAHA AHA Science

Calvin Yeang MD, PhD UC San Diego Cardiology UC San Diego Cardiology Fellows

ahajournals.org/doi/epub/10.11…

Really cool slide from Calvin Yeang MD, PhD at National Lipid Association Fall Clinical Update showing that regardless of Lp(a) levels, lifestyle plays a huge role!

A huge shoutout to first author Lotte de Boer, Bert Wiegman Sam Tsimikas, MD, Calvin Yeang MD, PhD, Merel, Alma Revers, John Kastelein, Barbara Hutten, Koos Zwinderman

Expanding field of RNA therapeutics to lower Lp(a), great to see these late-breaking data on lepodisiran, with discussion by Michelle O'Donoghue

AHA Science Steve Nicholls Pam R. Taub, MD❤️💃🏻 Karol Watson Sam Tsimikas, MD Harpreet Bhatia Calvin Yeang MD, PhD Christie Ballantyne Marlys Koschinsky Michael D. Shapiro

Lp(a) only tested in 0.3% of 5.5MM patients, despite having a 20%+ prevalence of elevated levels. Most common were those with family history of CVD, followed by IHD, aortic stenosis, and stroke. ahajournals.org/doi/full/10.11… JAHA Harpreet Bhatia Calvin Yeang MD, PhD Samm Hurst PhD, MA

Moderated by Calvin Yeang MD, PhD!

#KnowLpa
Final talk in the National Lipid Association opening session - by Calvin Yeang MD, PhD:
➡️ Statins are foundational, even if the slight ⬆️ Lp(a)
➡️ PCSK9s a good add-on option
➡️ Exciting therapies in development from Novartis, Amgen 🧪🔬🧬, Eli Lilly and Company & Silence Therapeutics

Family Heart Foundation

A5: if you have⬆️Lp(a): ♥️healthy diet & lifestyle are the 1st steps to ⬇️ heart attack & stroke risk from elevated Lp(a)
#KnowLpa Family Heart Foundation
Seth J. Baum MD Calvin Yeang MD, PhD Amit Khera Family Heart Foundation Katherine Wilemon*

Identification of MFSD5 as a receptor/co-factor in lipoprotein(a) uptake & calcific aortic valve disease & discovery of variant which enhances the effect of high lipoprotein(a) on aortic stenosis Calvin Yeang MD, PhD sasha Pradeep Natarajan Cassandra L. Clift, PhD ahajournals.org/doi/10.1161/CI…

A4: Even if you LDL is normal, you can have ⬆️ Lp(a)
#KnowLpa
🚨Lp(a)= risk enhancer: this means you may be at⬆️ risk for 🫀 disease & stroke.
🚨If you have⬆️Lp(a), so may your parents, siblings and children since it is genetic
Seth J. Baum MD Calvin Yeang MD, PhD Amit Khera

Join our amazing panelists today to chat about elevated Lipoprotein(a). #KnowLpa

Katherine Wilemon Josh Knowles Seth J. Baum MD Raul Santos Calvin Yeang MD, PhD Amit Khera Gissette Reyes-Soffer. MD FAHA Abha Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Courtney Riley MD Mackenzie Ames

Dive into our latest CE activity focusing on the pivotal aspects of Lp(a), delving into mgmt strategies for patients w/ elevated Lp(a) & unraveling the influence of population variances on Lp(a) levels. Marlys Koschinsky Christie Ballantyne Calvin Yeang MD, PhD

➡️lipid.org/unveiling_lpa

19) Here's where we are in #pelacarsen development, per pubmed.ncbi.nlm.nih.gov/34490591/. The 'big 🐶' is #HORIZON , published by Calvin Yeang MD, PhD et al in JACC Journals at 🔓 jacc.org/doi/10.1016/j.….

#KnowLpa
Excellent review and great recommendations on strategies to lower CV risk if you have ⬆️ Lp(a) from Gissette Reyes-Soffer. MD FAHA Erin D. Michos, M.D. Calvin Yeang MD, PhD & Christie Ballantyne!
➡️ Includes the new National Lipid Association screening recommendations!

Family Heart Foundation Family Heart Foundation Chief Medical Officer ASPC Association of Black Cardiologists

Sam Tsimikas, MD Calvin Yeang MD, PhD Are you referring to this study?
ahajournals.org/doi/10.1161/ci…
Colchicine seems to not exist for preventive cardiologists (outside US at least)

Congratulations to my amazing co-authors Harpreet Bhatia Calvin Yeang MD, PhD #PareshDesai , and #WenhongZhu !! Thx for including me ! ⬇️Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States | Journal of the American Heart Association ahajournals.org/doi/10.1161/JA…

High Lipoprotein(a): Actionable Strategies for Risk Assessment and Mit... sciencedirect.com/science/articl… Excellent review Gissette Reyes-Soffer. MD FAHA Calvin Yeang MD, PhD Erin D. Michos, M.D. ASPC Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 BCM Cardiology BCM_CVRI National Lipid Association The Texas Heart Institute Cardiometabolic Health Congress